Pricing
Login
Home
Charts
Search
Watchlist
Products

Medicamen Biotech Ltd

MEDICAMEQ
₹285.90-0.52%20 Nov 2026
Reports
Pharma Formulations

Medicamen Biotech Ltd

MEDICAMEQ
₹285.90
-0.52%
20 Nov 2026
Ask AI
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹402Cr
Close
Close Price
₹285.90
Industry
Industry
Pharma Formulations
PE
Price To Earnings
32.16
PS
Price To Sales
1.91
Revenue
Revenue
₹210Cr
Rev Gr TTM
Revenue Growth TTM
27.48%
PAT Gr TTM
PAT Growth TTM
41.93%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Revenue
RevenueCr
474743454530434747614855
Growth YoY
Revenue Growth YoY%
30.722.42.62.8-2.9-37.40.05.43.9104.811.316.2
Expenses
ExpensesCr
424240393831384243554446
Operating Profit
Operating ProfitCr
56357-2554549
OPM
OPM%
10.512.28.011.914.8-5.410.710.99.39.09.015.8
Other Income
Other IncomeCr
111005001210
Interest Expense
Interest ExpenseCr
121111111012
Depreciation
DepreciationCr
222320222222
PBT
PBTCr
332242232535
Tax
TaxCr
111111110111
PAT
PATCr
221132222424
Growth YoY
PAT Growth YoY%
-46.1-45.9-79.8-39.243.8-8.8100.0134.4-44.2139.315.695.3
NPM
NPM%
4.44.31.92.06.56.33.74.53.57.33.97.5
EPS
EPS₹
1.61.60.60.72.31.51.21.61.23.31.43.0
QuarterDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Revenue
RevenueCr
474743454530434747614855
Growth YoY
Revenue Growth YoY%
30.722.42.62.8-2.9-37.40.05.43.9104.811.316.2
Expenses
ExpensesCr
424240393831384243554446
Operating Profit
Operating ProfitCr
56357-2554549
OPM
OPM%
10.512.28.011.914.8-5.410.710.99.39.09.015.8
Other Income
Other IncomeCr
111005001210
Interest Expense
Interest ExpenseCr
121111111012
Depreciation
DepreciationCr
222320222222
PBT
PBTCr
332242232535
Tax
TaxCr
111111110111
PAT
PATCr
221132222424
Growth YoY
PAT Growth YoY%
-46.1-45.9-79.8-39.243.8-8.8100.0134.4-44.2139.315.695.3
NPM
NPM%
4.44.31.92.06.56.33.74.53.57.33.97.5
EPS
EPS₹
1.61.60.60.72.31.51.21.61.23.31.43.0

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
123126113115141179163198210
Growth
Revenue Growth%
2.4-10.22.422.027.3-9.321.727.5
Expenses
ExpensesCr
1061069392117157149178187
Operating Profit
Operating ProfitCr
171919242422142023
OPM
OPM%
13.915.217.120.416.912.48.59.910.9
Other Income
Other IncomeCr
421222633
Interest Expense
Interest ExpenseCr
111134344
Depreciation
DepreciationCr
233667777
PBT
PBTCr
181816181713101215
Tax
TaxCr
654324323
PAT
PATCr
1213121515971012
Growth
PAT Growth%
10.5-8.722.8-1.1-35.5-30.949.441.9
NPM
NPM%
9.810.610.812.910.55.34.05.05.7
EPS
EPS₹
10.310.99.912.211.87.55.27.28.9
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
123126113115141179163198210
Growth
Revenue Growth%
2.4-10.22.422.027.3-9.321.727.5
Expenses
ExpensesCr
1061069392117157149178187
Operating Profit
Operating ProfitCr
171919242422142023
OPM
OPM%
13.915.217.120.416.912.48.59.910.9
Other Income
Other IncomeCr
421222633
Interest Expense
Interest ExpenseCr
111134344
Depreciation
DepreciationCr
233667777
PBT
PBTCr
181816181713101215
Tax
TaxCr
654324323
PAT
PATCr
1213121515971012
Growth
PAT Growth%
10.5-8.722.8-1.1-35.5-30.949.441.9
NPM
NPM%
9.810.610.812.910.55.34.05.05.7
EPS
EPS₹
10.310.99.912.211.87.55.27.28.9
Sales CAGR
1 Year22%
3 Years12%
5 Years12%
TTM27%
EBITDA CAGR
1 Year41%
3 Years-6%
5 Years0%
TTM54%
PAT CAGR
1 Year49%
3 Years-13%
5 Years-4%
TTM42%
Avg. ROCE
1 Year5%
3 Years6%
5 Years8%
TTM6%
CFO / EBITDA
1 Year-169%
3 Years-86%
5 Years-49%
TTM-

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
Equity CapitalCr
121212121313131414
Reserves
ReservesCr
75109121134178194200253268
Current Liabilities
Current LiabilitiesCr
495653738385788868
Non Current Liabilities
Non Current LiabilitiesCr
1487336910
Total Liabilities
Total LiabilitiesCr
137181194226279295297372360
Current Assets
Current AssetsCr
9610496123163160165224206
Non Current Assets
Non Current AssetsCr
407798103115135133148153
Total Assets
Total AssetsCr
137181194226279295297372360
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
Equity CapitalCr
121212121313131414
Reserves
ReservesCr
75109121134178194200253268
Current Liabilities
Current LiabilitiesCr
495653738385788868
Non Current Liabilities
Non Current LiabilitiesCr
1487336910
Total Liabilities
Total LiabilitiesCr
137181194226279295297372360
Current Assets
Current AssetsCr
9610496123163160165224206
Non Current Assets
Non Current AssetsCr
407798103115135133148153
Total Assets
Total AssetsCr
137181194226279295297372360

Cash Flow

Consolidated
Standalone
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
413134-6-7-8-33
Investing Cash Flow
Investing Cash FlowCr
-15-37-18-8-6-6-1-3
Financing Cash Flow
Financing Cash FlowCr
-41964296-164
Net Cash Flow
Net Cash FlowCr
-14-51017-6-1128
Free Cash Flow
Free Cash FlowCr
-11-25-5-5-13-13-10-38
CFO To PAT
CFO To PAT%
35.896.3105.327.6-42.7-71.0-124.5-338.6
CFO To EBITDA
CFO To EBITDA%
25.367.066.417.4-26.4-30.3-58.9-169.4
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
413134-6-7-8-33
Investing Cash Flow
Investing Cash FlowCr
-15-37-18-8-6-6-1-3
Financing Cash Flow
Financing Cash FlowCr
-41964296-164
Net Cash Flow
Net Cash FlowCr
-14-51017-6-1128
Free Cash Flow
Free Cash FlowCr
-11-25-5-5-13-13-10-38
CFO To PAT
CFO To PAT%
35.896.3105.327.6-42.7-71.0-124.5-338.6
CFO To EBITDA
CFO To EBITDA%
25.367.066.417.4-26.4-30.3-58.9-169.4

Ratios

Consolidated
Standalone
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
567221652786829487612305402
Price To Earnings
Price To Earnings
47.216.653.852.855.944.586.231.632.2
Price To Sales
Price To Sales
4.61.85.86.85.92.73.81.51.9
Price To Book
Price To Book
6.51.84.95.44.32.42.91.11.3
EV To EBITDA
EV To EBITDA
33.511.934.634.334.922.646.316.417.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
25.527.629.542.939.639.537.738.238.2
OPM
OPM%
13.915.217.120.416.912.48.59.910.9
NPM
NPM%
9.810.610.812.910.55.34.05.05.7
ROCE
ROCE%
18.814.111.611.49.37.35.34.95.8
ROE
ROE%
13.911.09.110.27.74.63.13.74.3
ROA
ROA%
8.87.36.36.65.33.22.22.63.4
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
567221652786829487612305402
Price To Earnings
Price To Earnings
47.216.653.852.855.944.586.231.632.2
Price To Sales
Price To Sales
4.61.85.86.85.92.73.81.51.9
Price To Book
Price To Book
6.51.84.95.44.32.42.91.11.3
EV To EBITDA
EV To EBITDA
33.511.934.634.334.922.646.316.417.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
25.527.629.542.939.639.537.738.238.2
OPM
OPM%
13.915.217.120.416.912.48.59.910.9
NPM
NPM%
9.810.610.812.910.55.34.05.05.7
ROCE
ROCE%
18.814.111.611.49.37.35.34.95.8
ROE
ROE%
13.911.09.110.27.74.63.13.74.3
ROA
ROA%
8.87.36.36.65.33.22.22.63.4
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Market CapitalizationMkt CapCr660486435402338243237
Close PriceClose₹285.00406.05762.60285.9093.41680.10150.00
IndustryIndustryPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma Formulations
Price To EarningsPE29.2620.8915.1432.1611.1112.40
Price To SalesPS3.993.111.151.912.322.131.06
RevenueRevenueCr165156378210145114224
Revenue Growth TTMRev Gr TTM%55.2%19.7%27.5%6.1%28.2%26.7%
PAT Growth TTMPAT Gr TTM%39.5%290.6%41.9%-294.4%26.1%43.3%
Market CapitalizationMkt CapCr660486435402338243237
Close PriceClose₹285.00406.05762.60285.9093.41680.10150.00
IndustryIndustryPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma Formulations
Price To EarningsPE29.2620.8915.1432.1611.1112.40
Price To SalesPS3.993.111.151.912.322.131.06
RevenueRevenueCr165156378210145114224
Revenue Growth TTMRev Gr TTM%55.2%19.7%27.5%6.1%28.2%26.7%
PAT Growth TTMPAT Gr TTM%39.5%290.6%41.9%-294.4%26.1%43.3%
Annual Reports
FY2026
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
Quarterly Reports
FY2026
Sep 26
Result
PPT
Transcript
Summary
Jun 26
Result
PPT
Transcript
Summary
Mar 26
Result
PPT
Transcript
Summary
Dec 25
Result
PPT
Transcript
Summary
Sep 25
Result
PPT
Transcript
Summary
Mar 25
Result
PPT
Transcript
Summary
Dec 24
Result
PPT
Transcript
Summary
Sep 24
ResultPPT
Transcript
Summary
Mar 24
Result
PPT
Transcript
Summary
Dec 23
Result
PPT
Transcript
Summary
Sep 23
Result
PPT
Transcript
Summary
Jun 23
Result
PPT
Transcript
Summary
Mar 23
Result
PPT
Transcript
Summary
Dec 22
Result
PPT
Transcript
Summary
Sep 22
Result
PPT
Transcript
Summary
Jun 22
Result
PPT
Transcript
Summary
Mar 22
Result
PPT
Transcript
Summary
Dec 21
Result
PPT
Transcript
Summary
Sep 21
ResultPPT
Transcript
Summary
Jun 21
Result
PPT
Transcript
Summary
Mar 21
Result
PPT
Transcript
Summary
Sep 20
ResultPPT
Transcript
Summary
Jun 20
ResultPPT
Transcript
Summary
Annual Reports
Quarterly Reports
Sep 26
Result
PPT
Transcript
Summary
Jun 26
Result
PPT
Transcript
Summary
Mar 26
Result
PPT
Transcript
Summary
Dec 25
Result
PPT
Transcript
Summary
Sep 25
Result
PPT
Transcript
Summary
Mar 25
Result
PPT
Transcript
Summary
Dec 24
Result
PPT
Transcript
Summary
Sep 24
ResultPPT
Transcript
Summary
Mar 24
Result
PPT
Transcript
Summary
Dec 23
Result
PPT
Transcript
Summary
Sep 23
Result
PPT
Transcript
Summary
Jun 23
Result
PPT
Transcript
Summary
Mar 23
Result
PPT
Transcript
Summary
Dec 22
Result
PPT
Transcript
Summary
Sep 22
Result
PPT
Transcript
Summary
Jun 22
Result
PPT
Transcript
Summary
Mar 22
Result
PPT
Transcript
Summary
Dec 21
Result
PPT
Transcript
Summary
Sep 21
ResultPPT
Transcript
Summary
Jun 21
Result
PPT
Transcript
Summary
Mar 21
Result
PPT
Transcript
Summary
Sep 20
ResultPPT
Transcript
Summary
Jun 20
ResultPPT
Transcript
Summary
Load More
Interviews